Skip to Main Content

Paper Details

Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.
J Nucl Med
36
2014
Author NameAffiliation
Jure MurgicUniversity Hospital Center Sestre Milosrdnice
  • 1 - 1

Datasets

Release 1.2